STOCK TITAN

Chemomab director sells 2,304 ADS at ~$2.8

Chemomab Therapeutics Ltd. (CMMB) director Neil Harris Cohen reported both share sales and option awards.

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Chemomab Therapeutics Ltd. (CMMB) director Neil Harris Cohen reported both share sales and option awards. He sold 1,000 American Depositary Shares at $2.80 on August 28, 2026 and 1,304 ADS at $2.85 on August 27, 2026. Cohen also reported multiple prior grants of stock options to purchase ADS, many of which are noted as fully vested and exercisable as of this report.

Positive

  • None.

Negative

  • None.
Insider Cohen Neil Harris
Role Director
Sold 2,304 shs ($7K)
Type Security Shares Price Value
Sale American Depositary Shares 1,000 $2.80 $3K
Sale American Depositary Shares 1,304 $2.85 $4K
Grant/Award Stock option (right to buy American Depositary Shares) 5,172 $0.00 $0.00
Grant/Award Stock option (right to buy American Depositary Shares) F6 3,821 $0.00 $0.00
Grant/Award Stock option (right to buy American Depositary Shares) F5 2,520 $0.00 $0.00
Grant/Award Stock option (right to buy American Depositary Shares) F4 1,714 $0.00 $0.00
Grant/Award Stock option (right to buy American Depositary Shares) F3 1,705 $0.00 $0.00
Grant/Award Stock option (right to buy American Depositary Shares) F2 2,971 $0.00 $0.00
Grant/Award Stock option (right to buy American Depositary Shares) F1 172 $0.00 $0.00
Holdings After Transaction: Stock option (right to buy American Depositary Shares) — 54,785 contracts (Direct); American Depositary Shares — 33,000 shares (Direct)
Footnotes (6)
  1. F1. The options reported in this row were granted to the Reporting Person by the Issuer on July 16, 2020, and are fully vested and exercisable as of the date of this report.
  2. F2. The options reported in this row were granted to the Reporting Person by the Issuer on April 19, 2021, and are fully vested and exercisable as of the date of this report.
  3. F3. The options reported in this row were granted to the Reporting Person by the Issuer on March 7, 2022, and are fully vested and exercisable as of the date of this report.
  4. F4. The options reported in this row were granted to the Reporting Person by the Issuer on March 21, 2023, and are fully vested and exercisable as of the date of this report.
  5. F5. The options reported in this row were granted to the Reporting Person by the Issuer on March 18, 2024, and are fully vested and exercisable as of the date of this report.
  6. F6. The options reported in this row were granted to the Reporting Person by the Issuer on March 16, 2025, and are fully vested and exercisable as of the date of this report.
ADS sold 1,000 shares at $2.80 Sale of American Depositary Shares on 2026-08-28
ADS sold 1,304 shares at $2.85 Sale of American Depositary Shares on 2026-08-27
Stock options granted 5,172 options at $2.14 exercise price Grant on 2026-03-16, expiring 2036-03-16
Stock options granted 3,821 options at $6.16 exercise price Grant on 2025-03-16, fully vested as of report date
Stock options granted 2,520 options at $2.96 exercise price Grant on 2024-03-18, fully vested as of report date
Stock options granted 1,714 options at $6.48 exercise price Grant on 2023-03-21, fully vested as of report date
Stock options granted 1,705 options at $14.12 exercise price Grant on 2022-03-07, fully vested as of report date
Stock options granted 2,971 options at $109.04 exercise price Grant on 2021-04-19, fully vested as of report date
American Depositary Shares financial
"security_title": "American Depositary Shares""
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
Stock option financial
"security_title": "Stock option (right to buy American Depositary Shares)""
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price": "2.1400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
fully vested and exercisable financial
"are fully vested and exercisable as of the date of this report"
Rule 10b5-1 regulatory
"document-level Rule 10b5-1 checkbox"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

What insider transactions did CMMB director Neil Harris Cohen report in this Form 4?

Neil Harris Cohen reported two sales of Chemomab ADS totaling 2,304 shares and multiple stock option grants covering ADS, several of which are described as fully vested and exercisable as of the date of the report.

How many Chemomab (CMMB) shares did Neil Harris Cohen sell and at what prices?

Neil Harris Cohen sold 1,000 ADS at $2.80 on August 28, 2026 and 1,304 ADS at $2.85 on August 27, 2026, for total reported sales of 2,304 ADS across the two transactions.

What new stock option grant did Neil Harris Cohen receive for Chemomab (CMMB) ADS?

On March 16, 2026, Neil Harris Cohen was granted 5,172 stock options to buy Chemomab ADS at a $2.14 exercise price, expiring on March 16, 2036, with an exercise date shown as March 16, 2027.

Which Chemomab (CMMB) stock options held by Neil Harris Cohen are fully vested?

Footnotes state that option grants dated July 16, 2020, April 19, 2021, March 7, 2022, March 21, 2023, March 18, 2024, and March 16, 2025 are all fully vested and exercisable as of the date of this report.

Does this Chemomab (CMMB) Form 4 indicate trades under a Rule 10b5-1 plan?

The Form 4 data show the document-level Rule 10b5-1 checkbox as unchecked, and the footnotes do not mention any Rule 10b5-1 trading plan in connection with the reported transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cohen Neil Harris

(Last)(First)(Middle)
C/O CHEMOMAB THERAPEUTICS LTD.
1 KENDALL SQ, BLDG 1400E, STE 14-105

(Street)
CAMBRIDGE MASSACHUSETTS 02139

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Chemomab Therapeutics Ltd. [ CMMB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/27/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
American Depositary Shares08/27/2026S1,304D$2.8534,000D
American Depositary Shares08/28/2026S1,000D$2.833,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock option (right to buy American Depositary Shares)$52.807/16/2020A172 (1)07/16/2030American Depositary Shares172$0172D
Stock option (right to buy American Depositary Shares)$109.0404/19/2021A2,971 (2)04/19/2031American Depositary Shares2,971$03,143D
Stock option (right to buy American Depositary Shares)$14.1203/07/2022A1,705 (3)03/07/2032American Depositary Shares1,705$04,848D
Stock option (right to buy American Depositary Shares)$6.4803/21/2023A1,714 (4)03/21/2033American Depositary Shares1,714$06,562D
Stock option (right to buy American Depositary Shares)$2.9603/18/2024A2,520 (5)03/18/2034American Depositary Shares2,520$09,082D
Stock option (right to buy American Depositary Shares)$6.1603/16/2025A3,821 (6)03/16/2035American Depositary Shares3,821$012,903D
Stock option (right to buy American Depositary Shares)$2.1403/16/2026A5,17203/16/202703/16/2036American Depositary Shares5,172$018,075D
Explanation of Responses:
1. The options reported in this row were granted to the Reporting Person by the Issuer on July 16, 2020, and are fully vested and exercisable as of the date of this report.
2. The options reported in this row were granted to the Reporting Person by the Issuer on April 19, 2021, and are fully vested and exercisable as of the date of this report.
3. The options reported in this row were granted to the Reporting Person by the Issuer on March 7, 2022, and are fully vested and exercisable as of the date of this report.
4. The options reported in this row were granted to the Reporting Person by the Issuer on March 21, 2023, and are fully vested and exercisable as of the date of this report.
5. The options reported in this row were granted to the Reporting Person by the Issuer on March 18, 2024, and are fully vested and exercisable as of the date of this report.
6. The options reported in this row were granted to the Reporting Person by the Issuer on March 16, 2025, and are fully vested and exercisable as of the date of this report.
/s/ Neil Cohen08/31/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)